Summary of the technology
Alphanosos is active in animal feed, medical foods, and pharma, and with the right venture partners, to become a leader in botanical plant-based natural antimicrobial control, well-being and medicine through its R&D based on proprietary Artificial Intelligence. Alphanosos’ first patent-pending discoveries are incorporated into commercial products and generate its first revenues.
Description of the technology
Alphanosos is a privately held company incorporated in November 2014 in France.
We are leveraging our disruptive, AI-based, proprietary discovery process to discover and patent active ingredients and products based on plants with a history of safe human consumption to replace, with superior efficacy and reduced risks of side effects, many of the chemical products used as therapeutic drugs in the human and animal health industries.
We concentrate our discovery efforts on the selective killing of deleterious micro-organisms and cells. Our initial focus is on new antibiotics and anti-cancer products, with first products already in the post-discovery phase and a first patent application on anti-staphylococci products, for which we already obtained topical and systemic animal model results.
Early revenue is already generated by licenses for cosmetic usage of certain of these products, to be soon followed with licenses for veterinary applications and later for human drugs.
Intellectual property status
Patent pending in 71 countries.
Patent number :
Use of Proceeds
Small and Medium Enterprise
Additional information (attached documents)